OMEGA Diagnostics has stressed its confidence in the “potential global application” of the rapid test with Abingdon Health for Covid-19 that it is creating.
An update from Abingdon Health was noted by the Alva-based medical diagnostics company, welcoming confirmation that it continues to “work constructively with the Medicines and Healthcare products Regulatory Agency (MHRA) to try to facilitate approval for home use and self-testing of the AbC-19 rapid test in the UK.”
Abingdon said that when the United Kingdom was The Health and Social Care Department continues to have the right of first refusal to supply the AbC-19 rapid test through a commodity supply contract that runs through Feb. 14, in a total of 27 foreign territories, the UK-RTC is in touch with consumers and regulators to make potential use of the product outside the U.K.
Coronavirus: Oxford-AstraZeneca Covid vaccine approved for use in the United Kingdom
Colin King, Omega Diagnostics Chief Executive Officer, said, “We welcome the update from Abingdon Health this morning and look forward to updating investors in due course on the approval process for self-test use. We remain confident that the AbC-19 rapid test has potential for global use and we are pleased that the UK-RTC is engaged in constructive dialogue with interested customers and regulators around the world.”
A small drop of blood from a finger prick is used for the AbC-19 examination, with results shown within 20 minutes.
It is officially approved for use by healthcare professionals in the UK, and self-testing approval is being pursued by the UK-RTC.
Antibody tests detect whether a person has been infected with the coronavirus beforehand.
Omega is also collaborating with Bedfordshire-based Mologic on a rapid antibody test and plans to focus work on a rapid antigen test to identify individuals currently infected with coronavirus in 2021.
At its headquarters, the company raised its headcount from 60 at the beginning of the year to over 120. Construction work is expected to be completed by the end of the year on a £ 1 million manufacturing expansion, raising capacity from 500,000 to two million tests per week by April. In the coming months, up to 80 more workers are anticipated to be recruited.
In early trading, shares rose more than six percent to end up about 2 percent.